FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922263721> ?p ?o ?g. }

• W2922263721 abstract "560 Background: Level I evidence exists demonstrating the efficacy of the mTOR inhibitor everolimus (EVE) in decreasing tumor volume of syndromic angiomyolipomas (AMLs) among patients with Tuberous Sclerosis. No prospective data are available regarding the effect of mTOR inhibition on growth kinetics in patients with sporadic AMLs. Methods: We conducted a multi-institutional, prospective, phase 2 trial with an optimal two-stage Simon design in patients presenting with > 3cm sporadic AMLs who were candidates for surgical or percutaneous intervention. Response was defined as ≥25% volumetric reduction of the AML. Planned enrollment was 43 patients to test the null hypothesis at a 5% level of significance with 80% power. Baseline, 4- and 6-month volumetric analysis was performed by dynamic contrast-enhanced MRI (DCE-MRI). Patients received EVE 10mg for four 28-day cycles, at which point EVE was discontinued in those with < 25% volumetric reduction. Those with ≥ 25% volumetric reduction received two additional cycles of EVE. Dose reductions and interruptions were allowed to 5 mg QOD. Conservative stopping rules were established for toxicity, given the benign nature of AMLs. Results: The early stopping rules for both efficacy and toxicity were invoked. We enrolled 20 patients (median age = 68) from 5 centers with 21 sporadic AMLs. 11/20 (55%) patients completed 4 cycles of EVE, while 7/20 (35%) completed 6 cycles. Median days on treatment was 88 (2 cycles). 4/20 (20%) patients were withdrawn due to toxicity, while 8/20 (40%) withdrew due to personal preference. Dose reductions were required in 6/20 (30%) patients, and 5/20 (25%) patients had grade 3 toxicities which resolved upon discontinuation or dose reduction of EVE. At 4-month MRI, 10/16 (62.5%) patients had a ≥25% reduction in volume (mean = 54.1% decrease). At 6-month MRI, 8/12 (66.6%) patients had a ≥25% reduction in volume (mean = 51.5% decrease). Conclusions: EVE was effective in reducing tumor volume in patients with sporadic AMLs but was associated with a high rate of treatment termination due to patient preference or prespecified AEs. Neoadjuvant EVE may be useful in potentiating surgical resection of large or anatomically complex AMLs. Clinical trial information: NCT02539459." @default.
• W2922263721 created "2019-03-22" @default.
• W2922263721 creator A5002928582 @default.
• W2922263721 creator A5019379036 @default.
• W2922263721 creator A5022014477 @default.
• W2922263721 creator A5032422193 @default.
• W2922263721 creator A5033372450 @default.
• W2922263721 creator A5033589771 @default.
• W2922263721 creator A5037162298 @default.
• W2922263721 creator A5043554307 @default.
• W2922263721 creator A5048218662 @default.
• W2922263721 creator A5051789976 @default.
• W2922263721 creator A5062947850 @default.
• W2922263721 creator A5065101092 @default.
• W2922263721 creator A5065861894 @default.
• W2922263721 creator A5073175769 @default.
• W2922263721 creator A5075320625 @default.
• W2922263721 creator A5077644150 @default.
• W2922263721 creator A5080057051 @default.
• W2922263721 creator A5085172191 @default.
• W2922263721 creator A5087799211 @default.
• W2922263721 creator A5091629756 @default.
• W2922263721 date "2019-03-01" @default.
• W2922263721 modified "2023-09-25" @default.
• W2922263721 title "Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE)." @default.
• W2922263721 doi "https://doi.org/10.1200/jco.2019.37.7_suppl.560" @default.
• W2922263721 hasPublicationYear "2019" @default.
• W2922263721 type Work @default.
• W2922263721 sameAs 2922263721 @default.
• W2922263721 citedByCount "0" @default.
• W2922263721 crossrefType "journal-article" @default.
• W2922263721 hasAuthorship W2922263721A5002928582 @default.
• W2922263721 hasAuthorship W2922263721A5019379036 @default.
• W2922263721 hasAuthorship W2922263721A5022014477 @default.
• W2922263721 hasAuthorship W2922263721A5032422193 @default.
• W2922263721 hasAuthorship W2922263721A5033372450 @default.
• W2922263721 hasAuthorship W2922263721A5033589771 @default.
• W2922263721 hasAuthorship W2922263721A5037162298 @default.
• W2922263721 hasAuthorship W2922263721A5043554307 @default.
• W2922263721 hasAuthorship W2922263721A5048218662 @default.
• W2922263721 hasAuthorship W2922263721A5051789976 @default.
• W2922263721 hasAuthorship W2922263721A5062947850 @default.
• W2922263721 hasAuthorship W2922263721A5065101092 @default.
• W2922263721 hasAuthorship W2922263721A5065861894 @default.
• W2922263721 hasAuthorship W2922263721A5073175769 @default.
• W2922263721 hasAuthorship W2922263721A5075320625 @default.
• W2922263721 hasAuthorship W2922263721A5077644150 @default.
• W2922263721 hasAuthorship W2922263721A5080057051 @default.
• W2922263721 hasAuthorship W2922263721A5085172191 @default.
• W2922263721 hasAuthorship W2922263721A5087799211 @default.
• W2922263721 hasAuthorship W2922263721A5091629756 @default.
• W2922263721 hasConcept C121332964 @default.
• W2922263721 hasConcept C126322002 @default.
• W2922263721 hasConcept C126838900 @default.
• W2922263721 hasConcept C148898269 @default.
• W2922263721 hasConcept C185544564 @default.
• W2922263721 hasConcept C2775870830 @default.
• W2922263721 hasConcept C2779699572 @default.
• W2922263721 hasConcept C62520636 @default.
• W2922263721 hasConcept C71924100 @default.
• W2922263721 hasConceptScore W2922263721C121332964 @default.
• W2922263721 hasConceptScore W2922263721C126322002 @default.
• W2922263721 hasConceptScore W2922263721C126838900 @default.
• W2922263721 hasConceptScore W2922263721C148898269 @default.
• W2922263721 hasConceptScore W2922263721C185544564 @default.
• W2922263721 hasConceptScore W2922263721C2775870830 @default.
• W2922263721 hasConceptScore W2922263721C2779699572 @default.
• W2922263721 hasConceptScore W2922263721C62520636 @default.
• W2922263721 hasConceptScore W2922263721C71924100 @default.
• W2922263721 hasLocation W29222637211 @default.
• W2922263721 hasOpenAccess W2922263721 @default.
• W2922263721 hasPrimaryLocation W29222637211 @default.
• W2922263721 hasRelatedWork W2333409024 @default.
• W2922263721 hasRelatedWork W2575187343 @default.
• W2922263721 hasRelatedWork W2601367048 @default.
• W2922263721 hasRelatedWork W2970866199 @default.
• W2922263721 hasRelatedWork W3167238031 @default.
• W2922263721 hasRelatedWork W3184380755 @default.
• W2922263721 isParatext "false" @default.
• W2922263721 isRetracted "false" @default.
• W2922263721 magId "2922263721" @default.
• W2922263721 workType "article" @default.